JP2004520443A5 - - Google Patents

Download PDF

Info

Publication number
JP2004520443A5
JP2004520443A5 JP2002590934A JP2002590934A JP2004520443A5 JP 2004520443 A5 JP2004520443 A5 JP 2004520443A5 JP 2002590934 A JP2002590934 A JP 2002590934A JP 2002590934 A JP2002590934 A JP 2002590934A JP 2004520443 A5 JP2004520443 A5 JP 2004520443A5
Authority
JP
Japan
Prior art keywords
drug
composition
agents
vinyl acetate
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002590934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004520443A (ja
JP4541647B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/043111 external-priority patent/WO2002094215A2/en
Publication of JP2004520443A publication Critical patent/JP2004520443A/ja
Publication of JP2004520443A5 publication Critical patent/JP2004520443A5/ja
Application granted granted Critical
Publication of JP4541647B2 publication Critical patent/JP4541647B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002590934A 2000-11-20 2001-11-16 表面安定剤として共重合体を含むナノ粒子組成物 Expired - Fee Related JP4541647B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71511700A 2000-11-20 2000-11-20
PCT/US2001/043111 WO2002094215A2 (en) 2000-11-20 2001-11-16 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009292366A Division JP2010111685A (ja) 2000-11-20 2009-12-24 表面安定剤として共重合体を含むナノ粒子組成物

Publications (3)

Publication Number Publication Date
JP2004520443A JP2004520443A (ja) 2004-07-08
JP2004520443A5 true JP2004520443A5 (cg-RX-API-DMAC10.html) 2005-12-22
JP4541647B2 JP4541647B2 (ja) 2010-09-08

Family

ID=24872726

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002590934A Expired - Fee Related JP4541647B2 (ja) 2000-11-20 2001-11-16 表面安定剤として共重合体を含むナノ粒子組成物
JP2009292366A Pending JP2010111685A (ja) 2000-11-20 2009-12-24 表面安定剤として共重合体を含むナノ粒子組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009292366A Pending JP2010111685A (ja) 2000-11-20 2009-12-24 表面安定剤として共重合体を含むナノ粒子組成物

Country Status (8)

Country Link
EP (1) EP1341521B1 (cg-RX-API-DMAC10.html)
JP (2) JP4541647B2 (cg-RX-API-DMAC10.html)
AT (1) ATE419834T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001297844A1 (cg-RX-API-DMAC10.html)
CA (1) CA2428785C (cg-RX-API-DMAC10.html)
DE (1) DE60137362D1 (cg-RX-API-DMAC10.html)
ES (1) ES2317874T3 (cg-RX-API-DMAC10.html)
WO (1) WO2002094215A2 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CA2858733C (en) * 2004-12-31 2017-12-19 Iceutica Pty Ltd Nanoparticle compositions and methods for synthesis thereof
CN101287451A (zh) * 2005-05-23 2008-10-15 依兰药物国际有限公司 包含血小板聚集抑制剂的毫微粒和控制释放组合物
WO2007046632A1 (en) * 2005-10-18 2007-04-26 Amorepacific Corporation Cationic polymer nanoparticles encapsulating an active ingredients, and the cosmetic composition containing the same
WO2008002485A2 (en) * 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
AU2016203251B2 (en) * 2006-06-30 2017-11-16 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
JP5508003B2 (ja) * 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CA2759109A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
NZ710384A (en) 2009-04-24 2017-03-31 Iceutica Pty Ltd A novel formulation of indomethacin
PE20140166A1 (es) * 2010-10-01 2014-02-17 Cipla Ltd Composicion farmaceutica que comprende deferasirox
JP2014129317A (ja) * 2012-02-23 2014-07-10 Canon Inc 光音響造影剤用色素含有ナノ粒子
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2016134121A1 (en) 2015-02-20 2016-08-25 Cytec Industries Inc. Dialkyl sulfosuccinate compositions, method of making, and method of use
AU2017236423A1 (en) * 2016-03-24 2018-11-15 Locate Bio Limited Scaffolding material, methods and uses
GB201810925D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and methods of treatment
ES2984690T3 (es) 2020-06-26 2024-10-30 Algiax Pharmaceuticals Gmbh Composición de nanopartículas
CR20230376A (es) * 2021-01-11 2023-12-12 Bayer Healthcare Llc Formulaciones de gel líquido concentradas que contienen sales de naproxeno

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
ES2188883T3 (es) * 1996-07-08 2003-07-01 Ciba Sc Holding Ag Derivados de triazina como filtro uv en productos antisolares.
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Similar Documents

Publication Publication Date Title
US6969529B2 (en) Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
JP4541647B2 (ja) 表面安定剤として共重合体を含むナノ粒子組成物
JP5191073B2 (ja) ナノ粒子組成物における結晶成長および粒子凝集を防止するための方法
JP6534979B2 (ja) 低溶解性化合物の安定な複合体
JP4623966B2 (ja) 表面安定剤としてチロキサポールを含有する、濾過滅菌したブデソニドおよびベクロメタゾンのナノ粒子製剤
JP4380925B2 (ja) ナノパーティクル組成物用の表面安定剤としてのpeg誘導体化脂質の使用
US5534270A (en) Method of preparing stable drug nanoparticles
AU2005307797B2 (en) Injectable nanoparticulate olanzapine formulations
JP2005536512A5 (cg-RX-API-DMAC10.html)
TW201808273A (zh) 具有改善的藥物動力學的控釋γ-羥基丁酸鹽調配物
JP2006514688A5 (cg-RX-API-DMAC10.html)
CN101237868A (zh) 纳米粒氯吡格雷和阿司匹林组合制剂
JP2008524239A (ja) ナノ粒子のタクロリムス製剤
JP2005508939A5 (cg-RX-API-DMAC10.html)
CN1246058A (zh) 包含环孢菌素a的无油药物组合物
JP2010516704A (ja) 摂食/絶食による変動性を低減し、かつ経口バイオアベイラビリティーを改善するための難水溶性薬物の多相医薬製剤
JP2018517734A (ja) デフェラシロクスの改善された製剤およびその作製方法
JP2011251989A (ja) 低粘度液体剤形
MX2007012762A (es) Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina.
JP4865990B2 (ja) ナノ粒子メゲストロール製剤
EP4536192A1 (en) Amorphous dosage form containing ebselen
MXPA99012099A (en) Gelatine encapsulated solution dosage forms of sertraline